{"id":508682,"date":"2021-07-01T07:03:21","date_gmt":"2021-07-01T11:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/"},"modified":"2021-07-01T07:03:21","modified_gmt":"2021-07-01T11:03:21","slug":"eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/","title":{"rendered":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WATERTOWN, Mass., July  01, 2021  (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU.<\/p>\n<p align=\"left\">\u201cWe are pleased by the AMA\u2019s approval of this new Category III code, which we believe will provide physicians with an opportunity for a reimbursement pathway for intraocular procedures, including DEXYCU,\u201d said Scott Jones, Chief Commercial Officer of EyePoint Pharmaceuticals. \u201cDEXYCU is the first and only FDA-approved, single dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation. We believe the new code is an important step toward increased adoption of DEXYCU.\u201d<\/p>\n<p align=\"left\">Category III CPT codes are temporary codes for emerging technologies, services and procedures intended to be used for specific data collection or documentation. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.<\/p>\n<p align=\"left\">\n        <strong>About EyePoint Pharmaceuticals, Inc.<\/strong>\u00a0(Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company&#8217;s pipeline leverages its proprietary Durasert<sup>\u00ae<\/sup>\u00a0technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ<sup>\u00ae<\/sup>, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU<sup>\u00ae<\/sup>, for the treatment of postoperative inflammation following ocular surgery.\u00a0EyePoint Pharmaceuticals\u00a0is headquartered in\u00a0Watertown,\u00a0Massachusetts. To learn more about the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v9AqGtl3XhhMmZeOW_GZFn-9oEJooVs4b28L8NGqax5BGyc87R-coXGrAQGLuHXbnKE4aymdkM-gWMH3MqeJJXa-7pybSgf-3osXRmI4gyAcvQHL0dbFp_KIKrtqrs_RowjGgK7eAX6ypkFjO3xFYx3KN9vireBbhQ1CXAMh2QTrv3AP4Nf0YbZ-EEDUXPNGgRY9HWFMfkyToGeb0gxxxhktUKBGEFJwjPrj9rK_zQTM6CB4ETJkq9BtSDMpR8ykvJzZQQCHFsvkrUIdDepTYMzzLGmyL0gW44SCu3zfRBAB3ydAsd3fuZdM4O2PJ0x_y-cjtRE4d2bwQp9I8glMQJg4EsiwEQ6avn8gAi77emacpwTkK-xxjq2iFJshDENfYpQxyEbT5EOImWOkLbkDrCRYcMUbw-OzHmgofmo-jfY1lB5WekaDqHZjw-VryvwlFZr4VS_qwSdFYTDNu2l1j3dm1lAtFwScwvfCPs7byJIlsmUZA_8zwnNE126z2Qzl7R6eeIgD59qvbWdSCsfL3Ltt3DRKcnexBKNOdKZ7nEDbaAji_WkPIjn9s6s77-oW6yb7ur6VtRrw61D6mVki1wEeDpSZdXwaSrpPRgTejLdKwlIgv1kZ4kdtBPVdElJEWYnZELDVkPq0yk_NHbozSjB1Ni5xosCGH23fRH9Qr1OYsHMS5ln9-7_AvULoHKrQi9VPqFsjr9h8Z7nshcY8U3lMxQ0QioNh8Lz1ZF1j54a3ZNNaC6GU124pvrpS-unM7BaDv8BX7BjQP_odeT0iqg==\" rel=\"nofollow noopener\" target=\"_blank\">www.eyepointpharma.com<\/a>\u00a0and connect on Twitter and LinkedIn.<\/p>\n<p align=\"left\">SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as \u201cwill,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cintends,\u201d \u201ccontinue,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cmay,\u201d other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint\u2019s actual results to be materially different than those expressed in or implied by EyePoint\u2019s forward-looking statements. For EyePoint, this includes the continued impact of the COVID-19 pandemic on EyePoint\u2019s business, the medical community and the global economy and the impact of general business and economic conditions, our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the\u00a0U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with\u00a0Ocumension Therapeutics\u00a0and Equinox Science; termination or breach of current license agreements, including our agreements with\u00a0Ocumension Therapeutics\u00a0and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the\u00a0Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.<\/p>\n<p align=\"left\">\n        <strong>Investors:<\/strong>\n      <\/p>\n<p align=\"left\">Christina Tartaglia<br \/>Stern IR<br \/>Direct: 212-698-8700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=huNCklO2TMxboPZ1abYsBxNEdoLVz92oceLoxdimhj6pj1DRcLxCzFRx1QIbaQpqChtPPSjqvSe-Odn84eeNw0danomvGMEp6GSu3oOOu1lcwh5z1BcJBfCCTJqNAz8S\" rel=\"nofollow noopener\" target=\"_blank\">christina.tartaglia@sternir.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p align=\"left\">Green Room Public Relations<br \/>Caren Begun<br \/>Green Room Communications<br \/>Direct: (201) 396-8551\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=81ReXVGpk4qdXyb7LoOVPht-MG4QvKxqncalCCh6_pig4zvGYIh1cFMIAvr2WgrzwVQ44QI1KCihuf2lF346TfdNp6XzD7BT0UqajXP8aVY=\" rel=\"nofollow noopener\" target=\"_blank\">caren@greenroompr.com<\/a>\u00a0 \u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a452191d-620e-4275-9083-ad74bcedf235\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU. \u201cWe are pleased by the AMA\u2019s approval of this new Category III code, which we believe will provide physicians with an opportunity for a reimbursement pathway for intraocular procedures, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508682","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU. \u201cWe are pleased by the AMA\u2019s approval of this new Category III code, which we believe will provide physicians with an opportunity for a reimbursement pathway for intraocular procedures, &hellip; Continue reading &quot;EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T11:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association\",\"datePublished\":\"2021-07-01T11:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/\"},\"wordCount\":913,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/\",\"name\":\"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\",\"datePublished\":\"2021-07-01T11:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/","og_locale":"en_US","og_type":"article","og_title":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk","og_description":"WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) &#8212; EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU. \u201cWe are pleased by the AMA\u2019s approval of this new Category III code, which we believe will provide physicians with an opportunity for a reimbursement pathway for intraocular procedures, &hellip; Continue reading \"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T11:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association","datePublished":"2021-07-01T11:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/"},"wordCount":913,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/","name":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=","datePublished":"2021-07-01T11:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzY5OSM0Mjc4Mjg1IzIwMDU4MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eyepoint-pharmaceuticals-announces-new-category-iii-cpt-code-for-dexycu-intraocular-suspension-approved-by-the-american-medical-association\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU\u00ae Intraocular Suspension, Approved by the American Medical Association"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508682"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508682\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}